source
- Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitisBoth Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
- US panel warns China’s biotech plan could dominate sector and threaten drug supply chainA congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…